Neurology Central

Siponimod could improve outcome in patients with SPMS

Novartis has announced today (23 March 2018) that results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) could reduce the risk of disability progression in patients.

The results, which were published in The Lancet, revealed a significant reduction in the risk of 3- (primary endpoint) and 6-month confirmed disability progression with siponimod versus placebo.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.